Longevity Health Holdings Inc.(XAGE)Earnings, Financials & Key Ratios
XAGE•NASDAQ
$0.32
$7M mkt cap·Price updated May 7, 2026
AboutLongevity Health Holdings Inc focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.Show more
- Revenue$50K
- EBITDA-$5M+5.7%
- Net Income-$10M+32.9%
- EPS (Diluted)-0.50+32.4%
- Gross Margin87.37%
- EBITDA Margin-9541.79%
- Operating Margin-9933.82%
- Net Margin-20605.47%
- ROE-103.49%-65.8%
- ROIC-37.98%
- Interest Coverage-101.98-1638.3%
XAGE Key Insights
Longevity Health Holdings Inc. (XAGE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 18 (bottom 18%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
XAGE Price & Volume
Longevity Health Holdings Inc. (XAGE) stock price & volume — 10-year historical chart
Loading chart...
XAGE Growth Metrics
Longevity Health Holdings Inc. (XAGE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM139.43%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM8.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-187.75%
Return on Capital
10 Years-49.97%
5 Years-49.97%
3 Years-49.97%
Last Year-47.51%
XAGE Peer Comparison
Longevity Health Holdings Inc. (XAGE) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HIMS | 6.63B | 25.67 | 50.32 | 59% | 5.47% | 23.73% | 2.07 | |
 MGRX | 5.54M | 0.34 | -0.08 | -15.81% | -42.45% | -114.63% | 0.02 | |
 WELL | 149.25B | 213.02 | 153.25 | 35.82% | 12.31% | 3.49% | 0.49 | |
 GDRX | 973.26M | 2.84 | 33.29 | 0.57% | 3.74% | 4.75% | 0.10 | |
 TALK | 867.72M | 5.18 | 129.50 | 22% | 3.4% | 6.89% | ||
 AMWL | 129.49M | 7.75 | -1.30 | -1.98% | -48.16% | -33.48% | 0.02 | |
 TDOC | 1.26B | 6.96 | -6.11 | -1.54% | -6.81% | -12.37% | 0.75 | |
 OPRX | 123.59M | 6.63 | 24.56 | 18.78% | 4.69% | 4.22% | 0.04 |
Compare XAGE vs Peers
Longevity Health Holdings Inc. (XAGE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XAGE Income Statement
Longevity Health Holdings Inc. (XAGE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 50.32K | 1.46M |
| Revenue Growth % | - | - | - | - | 139.43% |
| Cost of Goods Sold | 0 | 242.56K | 124.79K | 6.36K | 661.19K |
| COGS % of Revenue | - | - | - | 12.63% | - |
| Gross Profit | 0▲ 0% | -242.56K▲ 0% | -124.79K▲ 48.6% | 43.96K▲ 135.2% | 796.12K▲ 0% |
| Gross Margin % | - | - | - | 87.37% | 54.63% |
| Gross Profit Growth % | - | - | 48.55% | 135.23% | - |
| Operating Expenses | 1.94M | 5.27M | 5.09M | 5.04M | 6.64M |
| OpEx % of Revenue | - | - | - | 10021.18% | - |
| Selling, General & Admin | 863.33K | 3.22M | 2.6M | 3.9M | 5.76M |
| SG&A % of Revenue | - | - | - | 7759.97% | - |
| Research & Development | 982.84K | 2.2M | 2.5M | 1.05M | 842.53K |
| R&D % of Revenue | - | - | - | 2095.29% | - |
| Other Operating Expenses | 94.16K | -148.26K | 0 | 83.49K | 33.77K |
| Operating Income | -467.43K▲ 0% | -5.51M▼ 1078.3% | -5.22M▲ 5.3% | -5M▲ 4.2% | -5.84M▲ 0% |
| Operating Margin % | - | - | - | -9933.82% | -400.96% |
| Operating Income Growth % | - | -1078.28% | 5.27% | 4.19% | - |
| EBITDA | -225.31K | -5.27M | -5.09M | -4.8M | -5.65M |
| EBITDA Margin % | - | - | - | -9541.79% | -387.64% |
| EBITDA Growth % | - | -2236.85% | 3.28% | 5.72% | -153.76% |
| D&A (Non-Cash Add-back) | 242.12K | 242.56K | 124.79K | 197.26K | 194.12K |
| EBIT | -329.38K | -5.3M | -15.32M | -10.7M | -5.91M |
| Net Interest Income | -2.49M | -1.5M | -889.32K | -49.02K | -20.13K |
| Interest Income | 8.09K | 2.25M | 0 | 0 | 0 |
| Interest Expense | 2.5M | 3.75M | 889.32K | 49.02K | 20.13K |
| Other Income/Expense | 138.05K | -3.54M | -10.99M | -5.75M | 9.63K |
| Pretax Income | -329.38K▲ 0% | -9.05M▼ 2648.0% | -16.21M▼ 79.0% | -10.75M▲ 33.7% | -5.83M▲ 0% |
| Pretax Margin % | - | - | - | -21359.64% | -400.3% |
| Income Tax | 0 | 0 | 0 | -97.28K | -97.28K |
| Effective Tax Rate % | 0% | 0% | 0% | 0.91% | 1.67% |
| Net Income | -6.48M▲ 0% | -9.05M▼ 39.7% | -15.45M▼ 70.6% | -10.37M▲ 32.9% | -5.74M▲ 0% |
| Net Margin % | - | - | - | -20605.47% | -393.63% |
| Net Income Growth % | - | -39.7% | -70.64% | 32.87% | 8.9% |
| Net Income (Continuing) | -329.38K | -9.05M | -16.21M | -10.65M | -5.74M |
| Discontinued Operations | 0 | 0 | 760.16K | 282.2K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01▲ 0% | -0.50▼ 4487.2% | -0.74▼ 48.0% | -0.50▲ 32.4% | -3.33▲ 0% |
| EPS Growth % | - | -4487.16% | -48% | 32.43% | -187.75% |
| EPS (Basic) | -0.01 | -0.50 | -0.74 | -0.50 | - |
| Diluted Shares Outstanding | 19.77M | 19.77M | 20.77M | 20.91M | 1.72M |
| Basic Shares Outstanding | 19.77M | 19.77M | 20.77M | 20.91M | 1.72M |
| Dividend Payout Ratio | - | - | - | - | - |
XAGE Balance Sheet
Longevity Health Holdings Inc. (XAGE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Total Current Assets | 178.7K | 605.54K | 62.9M | 955.55K | 2.84M |
| Cash & Short-Term Investments | 774.19K | 128.15K | 2.91M | 157.14K | 1.11M |
| Cash Only | 774.19K | 128.15K | 2.91M | 157.14K | 1.11M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 204.56K | 305.93K | 46.52K |
| Days Sales Outstanding | - | - | - | 2.22K | 69.21 |
| Inventory | 0 | 0 | 0 | 108.7K | 1.01M |
| Days Inventory Outstanding | - | - | - | 6.24K | 507.09 |
| Other Current Assets | -794.47K | 422.32K | 59.02M | 86.31K | 301.84K |
| Total Non-Current Assets | 1.38M | 1.14M | 1.05M | 518.43K | 455.03K |
| Property, Plant & Equipment | 1.35M | 1.11M | 1.02M | 498.79K | 438.8K |
| Fixed Asset Turnover | - | - | - | 0.10x | 3.03x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 33.22K | 28.7K | 24.19K | 19.64K | 16.23K |
| Long-Term Investments | 154.45M | 156.69M | 0 | 0 | 0 |
| Other Non-Current Assets | -154.45M | -156.69M | 0 | 0 | 0 |
| Total Assets | 1.56M▲ 0% | 1.75M▲ 12.3% | 63.95M▲ 3557.3% | 1.47M▼ 97.7% | 3.3M▲ 0% |
| Asset Turnover | - | - | - | 0.03x | 0.49x |
| Asset Growth % | - | 12.29% | 3557.25% | -97.7% | -134.71% |
| Total Current Liabilities | 15.8M | 7.3M | 38.5M | 5.88M | 6.84M |
| Accounts Payable | 871.31K | 2.14M | 4.42M | 4.06M | 4.17M |
| Days Payables Outstanding | - | 3.22K | 12.92K | 233K | 2.4K |
| Short-Term Debt | 8.6M | 2.78M | 1.29M | 241.16K | 286.06K |
| Deferred Revenue (Current) | 2.37M | 1.39M | 0 | 0 | 0 |
| Other Current Liabilities | 1.96M | 349.26K | 31.35M | 0 | 116.81K |
| Current Ratio | 0.01x | 0.08x | 1.63x | 0.16x | 0.16x |
| Quick Ratio | 0.01x | 0.08x | 1.63x | 0.14x | 0.14x |
| Cash Conversion Cycle | - | - | - | -224.54K | -1.83K |
| Total Non-Current Liabilities | 15.33M | 32.24M | 697.72K | 309.94K | 435.35K |
| Long-Term Debt | 922 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 961.91K | 827.73K | 697.72K | 309.94K | 1.1M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 14.37M | 31.42M | 0 | 0 | 731.02K |
| Total Liabilities | 31.13M | 39.54M | 39.2M | 6.19M | 7.28M |
| Total Debt | 9.69M | 3.74M | 2.14M | 638.99K | 618.63K |
| Net Debt | 8.91M | 3.61M | -776.01K | 481.85K | -490.6K |
| Debt / Equity | - | - | 0.09x | - | -0.16x |
| Debt / EBITDA | - | - | - | - | -0.11x |
| Net Debt / EBITDA | - | - | - | - | 0.09x |
| Interest Coverage | -0.19x | -1.47x | -5.87x | -101.98x | -293.50x |
| Total Equity | -29.58M▲ 0% | -37.79M▼ 27.8% | 24.75M▲ 165.5% | -4.71M▼ 119.0% | -3.98M▲ 0% |
| Equity Growth % | - | -27.77% | 165.49% | -119.04% | -462.79% |
| Book Value per Share | -1.50 | -1.91 | 1.19 | -0.23 | -2.31 |
| Total Shareholders' Equity | -29.58M | -37.79M | 24.75M | -4.71M | -3.98M |
| Common Stock | 36.92K | 14.53K | 2.31K | 2.09K | 178 |
| Retained Earnings | -32.77M | -42.38M | -58.5M | -68.87M | -73.69M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -31.42M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
XAGE Cash Flow Statement
Longevity Health Holdings Inc. (XAGE) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Cash from Operations | -1.18M | -3.81M | -8.35M | -4.39M | -4.39M |
| Operating CF Margin % | - | - | - | -8722.42% | - |
| Operating CF Growth % | - | -223.83% | -119.06% | 47.43% | 129.79% |
| Net Income | -6.48M | -9.05M | -15.45M | -11.8M | -5.74M |
| Depreciation & Amortization | 242.12K | 242.56K | 124.79K | 197.26K | 215.5K |
| Stock-Based Compensation | 246.8K | 636.37K | 667.68K | 827.04K | 575.33K |
| Deferred Taxes | 2.52M | -194.59K | 0 | 0 | 0 |
| Other Non-Cash Items | 1.35M | 2.22M | 9.73M | 5.72M | -275.22K |
| Working Capital Changes | 952.69K | 2.34M | -3.42M | 669.49K | 1.33M |
| Change in Receivables | 0 | 0 | -204.56K | -101.38K | -52.17K |
| Change in Inventory | 0 | 0 | 204.56K | -108.7K | 323.58K |
| Change in Payables | 80.32K | 1.06M | -449.87K | -359.14K | -353.17K |
| Cash from Investing | -7.27K | -7.16K | -30.47K | -748.8K | -164.22K |
| Capital Expenditures | -7.27K | -7.16K | -30.47K | 0 | -14.22K |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | -748.8K | -150K |
| Investments | - | - | - | - | - |
| Other Investing | 154.44M | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.2M | 3.93M | 11.16M | 2.38M | 3.93M |
| Debt Issued (Net) | 1.12M | 2.75M | -3.2M | -218.49K | -466.39K |
| Equity Issued (Net) | 3.19K | 1000K | 41.07K | 1000K | 3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -2.29K | 0 | 0 | 0 |
| Other Financing | 67.82K | 125.88K | 14.32M | -86.31K | -86.31K |
| Net Change in Cash | 11.21K▲ 0% | 115.79K▲ 932.7% | 2.78M▲ 2304.7% | -2.76M▼ 199.0% | -28.1K▲ 0% |
| Free Cash Flow | -1.18M▲ 0% | -3.44M▼ 190.2% | -8.38M▼ 143.9% | -4.39M▲ 47.6% | -3.81M▲ 0% |
| FCF Margin % | - | - | - | -8722.42% | -261.39% |
| FCF Growth % | - | -190.17% | -143.86% | 47.62% | 43.66% |
| FCF per Share | -0.06 | -0.17 | -0.40 | -0.21 | -0.21 |
| FCF Conversion (FCF/Net Income) | 0.18x | 0.42x | 0.54x | 0.42x | 0.66x |
| Interest Paid | 0 | 0 | 283.53K | 29.47K | 15.07K |
| Taxes Paid | 0 | 0 | 750K | 0 | 0 |
XAGE Key Ratios
Longevity Health Holdings Inc. (XAGE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|
| Return on Equity (ROE) | - | -62.41% | -103.49% | 141.35% |
| Return on Invested Capital (ROIC) | - | - | -37.98% | -37.98% |
| Gross Margin | - | - | 87.37% | 54.63% |
| Net Margin | - | - | -20605.47% | -393.63% |
| Debt / Equity | - | 0.09x | - | -0.16x |
| Interest Coverage | -1.47x | -5.87x | -101.98x | -293.50x |
| FCF Conversion | 0.42x | 0.54x | 0.42x | 0.66x |
| Revenue Growth | - | - | - | 139.43% |
XAGE Frequently Asked Questions
Longevity Health Holdings Inc. (XAGE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Longevity Health Holdings Inc. (XAGE) reported $1.5M in revenue for fiscal year 2024.
Longevity Health Holdings Inc. (XAGE) grew revenue by 0.0% over the past year. Growth has been modest.
Longevity Health Holdings Inc. (XAGE) reported a net loss of $5.7M for fiscal year 2024.
Dividend & Returns
Longevity Health Holdings Inc. (XAGE) has a return on equity (ROE) of -103.5%. Negative ROE indicates the company is unprofitable.
Longevity Health Holdings Inc. (XAGE) had negative free cash flow of $3.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More XAGE
Longevity Health Holdings Inc. (XAGE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates